FBIO Key Statistics, Chart & Performance
The current stock price of FBIO is 3.72 USD. In the past month the price increased by 8.45%. In the past year, price increased by 98.93%.
FBIO Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to FBIO. When comparing the yearly performance of all stocks, FBIO is one of the better performing stocks in the market, outperforming 94.71% of all stocks.
FBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FBIO. Both the profitability and financial health of FBIO have multiple concerns.
FBIO Financial Highlights
Over the last trailing twelve months FBIO reported a non-GAAP Earnings per Share(EPS) of -1.62. The EPS increased by 57.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.94% | ||
| ROE | -9.55% | ||
| Debt/Equity | 0.86 |
FBIO Forecast & Estimates
8 analysts have analysed FBIO and the average price target is 10.97 USD. This implies a price increase of 194.76% is expected in the next year compared to the current price of 3.72.
For the next year, analysts expect an EPS growth of 80.35% and a revenue growth 24.62% for FBIO
FBIO Ownership
FBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About FBIO
Company Profile
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Company Info
FORTRESS BIOTECH INC
1111 Kane Concourse, Suite 301
Bay Harbor Islands FLORIDA 10014 US
CEO: Lindsay A. Rosenwald
Employees: 101
Phone: 17816524500
FORTRESS BIOTECH INC / FBIO FAQ
What does FBIO do?
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Can you provide the latest stock price for FORTRESS BIOTECH INC?
The current stock price of FBIO is 3.72 USD. The price increased by 6.9% in the last trading session.
What is the dividend status of FORTRESS BIOTECH INC?
FBIO does not pay a dividend.
What is the ChartMill technical and fundamental rating of FBIO stock?
FBIO has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in FORTRESS BIOTECH INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FBIO.
What is the expected growth for FBIO stock?
The Revenue of FORTRESS BIOTECH INC (FBIO) is expected to grow by 24.62% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for FORTRESS BIOTECH INC?
FORTRESS BIOTECH INC (FBIO) has a market capitalization of 115.47M USD. This makes FBIO a Micro Cap stock.